While a large fraction of recurrent and/or conserved mutations can directly or indirectly be considered NAMs as they typically perturb signaling networks (as exemplified here with BRAF V600E) and they typically operate as functional driver mutations, in this study we have demonstrated that non-recurrent and non-conserved mutations also can be functional NAMs.
This can probably be explained by the fact that women with non recurrent AUC are otherwise healthy subjects, uncommonly exposed to antibiotics and thus to any ecological adverse effect on their gut flora.
Therefore, it is possible that in non-recurrent tumors, in which the POSTN module is repressed, the stroma has fewer interactions with tumor cells, somehow disabling metastasis development.
The possibility that additional non-recurrent driver mutations contributed to pathogenesis cannot be excluded; in a further four cases of APL with these two mutations, additional cancer-associated tier 1 mutations were identified.
Thus far, over 200 non recurrent RET coding sequence (CDS) mutations have been identified in HSCR patients.
Expression of ANRIL in non recurrent and recurrent tumor samples.
One explanation for the lack of adoption of previously developed Sub1 varieties such as IR49830-7-1-2-2 (Mackill 2006) was that genomic regions from the non-recurrent parent remained.
'However, given enough time, one may predict that the effects of this non-recurrent, historic event at the current range limit will be transient and eventually assume a level of genetic variation either by immigration or mutation comparable to the remaining distribution area.
Thus Fig. 4 shows that: In both non-recurrent and recurrent cases, the postoperative midline displacement on the 1st postoperative day was significantly reduced in both the unilateral and bilateral groups when compared with the preoperative values (p < 0.001).
Thus Fig. 3 shows that: In both non-recurrent and recurrent cases, the thickness of residual haematoma cavity on the 1st postoperative day was significantly reduced in the unilateral and bilateral groups when compared with the preoperative values (p < 0.001).
Finally, it is noteworthy that filtering out non-recurrent somatic variants we significantly reduce the number putative driver mutations to a relatively small set of variants (~170,000), which are held by ~96% of the patients (see Table 1).
